Compare BSL & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSL | IMUX |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.7M | 155.8M |
| IPO Year | 2010 | 2013 |
| Metric | BSL | IMUX |
|---|---|---|
| Price | $12.87 | $7.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $43.09 |
| AVG Volume (30 Days) | 43.6K | ★ 382.7K |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | ★ 9.55% | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.45 | $0.51 |
| 52 Week High | $13.99 | $17.43 |
| Indicator | BSL | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 41.12 | 33.34 |
| Support Level | $12.85 | $6.35 |
| Resistance Level | $13.03 | $8.60 |
| Average True Range (ATR) | 0.08 | 0.65 |
| MACD | -0.01 | 0.17 |
| Stochastic Oscillator | 25.44 | 36.89 |
Blackstone Senior Floating Rate Term Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. The fund also invests in second-lien loans and high yield bonds and employs financial leverage which may increase the risk to the Fund.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.